Basic demographic and clinical characteristics of participants across trials of pulmonary arterial hypertension (PAH) treatments
| Randomised participants | 124 (45–267) |
| Trials | 53 |
| Age (years) | 48.7 (44.6–51.1) |
| Female (%) | 78.8 (75.1–81.4) |
| 6MWD (m) | 349 (333.4–372) |
| NYHA/WHO functional class (%) | |
| I | 0 (0–0.4) |
| II | 34 (9.2–50.7) |
| III | 60.7 (51–74.1) |
| IV | 1.2 (0–5) |
| PAH aetiology | |
| Idiopathic/heritable | 5400 (51) |
| CTD-associated | 2832 (26.5) |
| HIV-associated | 80 (1) |
| Other | 2358 (21.5) |
Data are presented as median (interquartile range), n or n (%). Full details of the included trials in the network meta-analysis are given in supplementary material S5 and S6. 6MWD: 6-min walk distance; NYHA: New York Heart Association; WHO: World Health Organization; CTD: connective tissue disease.